El-Hussuna, Alaa, M.D.

Quick facts

Phase 2 pipeline

• Anti-tumor necrosis factor alpha agents · Immunology
  Anti-tumor necrosis factor alpha agents work by blocking the action of tumor necrosis factor-alpha (TNF-alpha), a protein involved in systemic inflammation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• El-Hussuna, Alaa, M.D. portfolio CI brief
• El-Hussuna, Alaa, M.D. pipeline updates RSS